Platelet-rich fibrin therapy in the management of nonhealing trophic ulcers due to underlying leprous neuropathy

J Cutan Aesthet Surg. 2024 Jul-Sep;17(3):262-265. doi: 10.4103/JCAS.JCAS_192_22. Epub 2023 Jun 27.

Abstract

Autologous platelet-rich fibrin (PRF) therapy is beneficial in the treatment of nonhealing ulcers. We present a case series of nonhealing, trophic ulcers with underlying leprous neuropathy, treated successfully with PRF therapy. It was a prospective study, conducted in a tertiary care hospital in the western Maharashtra, India between April 2021 and March 2022. A total of 11 patients with 18 nonhealing trophic ulcers were included in the study and consisted of 8 men and 3 women. The patient's median age was 41 years (range, 33-68), the median size of the ulcers was 4 cm2 (range: 1-12 cm2), the median duration of ulcers was 20 weeks (16-30 weeks), and time to heal after starting treatment was 4 weeks (range: 1-8 weeks). PRF is an easy-to-use, simple, safe, effective, and economical treatment for the management of trophic ulcers.

Keywords: Hansen disease; Leprosy; Nonhealing ulcer; PRF; Platelet rich fibrin; Treatment; Trophic ulcer.

Grants and funding

Financial support and sponsorship